Is APR Corporation profitable in 2025?

Yes. APR reported FY2025 consolidated revenue of KRW 1.53 trillion (about USD 1.05 billion), up 111% YoY, with operating profit of KRW 365.4 billion (+198% YoY) and a 24% operating margin, per company results dated 2026-02-04.

Who is Medicube's biggest competitor?

LG Household & Health Care's LG Pra.L device brand grew 447% in the five months after LG H&H acquired it in June 2025. Amorepacific is also contesting with AI-diagnostic tech like Skinsight (CES 2026 award) and its June 2026 Facial Aging Map.

Could AI replace Medicube's beauty devices?

Unlikely to replace the physical hardware, but rival Amorepacific has built AI-diagnostic layers (Skinsight, Dr. AMORE Facial Aging Map, June 2026) that APR has no public equivalent for as of July 2026, risking a differentiation gap rather than product replacement.

Is APR Corporation still growing in 2026?

Yes. Q1 2026 revenue reached KRW 593.4 billion, up 123.0% YoY, with operating profit of KRW 152.3 billion (+173.7% YoY) and overseas sales at roughly 90% of total, per results reported 2026-05-07.

Has APR overtaken Amorepacific and LG H&H in value?

By August 2025, APR's market cap reached about KRW 8.5 trillion, surpassing Amorepacific (~KRW 7 trillion) and LG H&H (~KRW 4.6 trillion). By May 2026 APR's cap had climbed to roughly KRW 16 trillion.

Is APR/Medicube facing any controversy in 2026?

In July 2026, APR publicly rebutted allegations that its '625% absorption rate' marketing claim echoed Korean War symbolism, releasing Tego Science lab test data in its defense; the controversy was still active as of July 7, 2026.

Consumer brands · South Korea

APR Corporation

apr.co.kr ↗

Korean beauty-tech maker of Medicube skincare devices and cosmetics, IPO'd 2024.

Protection under test

Assessed 26 July 2026 · Evidence as of 26 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 26 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, first test of whether 100%+ YoY growth decelerates

The call

APR leads Korea's beauty-device market on brand and distribution, while LG H&H and Amorepacific build rival devices and AI diagnostics without yet pulling share away.

APR Corporation makes skincare devices sold mostly overseas (like at Sephora and Nykaa) and has sold over 6 million units with strong profits. It is hard to beat right now because of its brand name, the stores that sell it, and customers who already own its products and buy more, but there is nothing that stops other companies from making similar devices. LG and Amorepacific, two much larger Korean beauty companies, have already launched their own devices and are copying APR's success, and Amorepacific is adding AI technology to diagnose skin problems, which APR has not done yet. The biggest question is whether APR can keep growing as fast when the market gets bigger and these rivals grab market share, and whether it can launch a medical-grade device that regulators approve before its competitors do.

Why

AI pressure: Amorepacific's AI skin-diagnostic tools (Skinsight, Dr. AMORE, Samsung AI Beauty Mirror). Amorepacific pitches AI skin diagnostics as a reason to buy its devices instead of Medicube's; APR has no equivalent AI layer yet. Could AI do the core job? Only partly.

Bigger players: LG Household & Health Care (LG Pra.L) and Amorepacific device lines. Both Korean giants now sell competing beauty devices; LG Pra.L grew 447% in five months post-acquisition. Could a giant copy it? Yes, easily.

What protects it. Brand heat plus executed global distribution: 6M+ devices sold, 90% international sales, live in Sephora, Ulta, and Nykaa.

What would change this call

APR's Q2 2026 earnings report (due ~August 2026). Shows whether 100%+ revenue growth is decelerating as LG H&H and Amorepacific scale rival devices.
LG H&H discloses LG Pra.L sales figures or growth rate for H1 2026. Confirms whether the 447% post-acquisition growth trajectory is sustained or fading.
Medicube's Sephora or Ulta Beauty category ranking in late 2026. Indicates whether the brand is cooling in key Western retail channels versus early 2026 highs.

Key numbers

FY2025 revenue KRW 1.53 trillion, up 111% YoY (2026-02-04)
Overseas sales rose from 55% to 80% of total in 2025 (2026-02-04)
Medicube devices passed 6 million units sold (2026-01-26)

Named risks

Reputational/regulatory exposure from '625% absorption rate' ad controversy active July 2026. Severity: medium
Incumbents LG H&H (LG Pra.L +447%) and Amorepacific rapidly scaling competing device lines. Severity: high
Growth deceleration risk as revenue base scales, with stock pricing in sustained 100%+ YoY growth. Severity: high
Differentiation gap versus Amorepacific's AI skin-diagnostic platforms (Skinsight, Dr. AMORE). Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
LG Household & Health Care	gaining on	LG Pra.L sales rose 447% in five months after LG H&H's June 2025 acquisition, reported 2026-06-20
Amorepacific	contesting	Launched AI Facial Aging Map (2026-06-15) and CES-award Skinsight (2025-11-13); no APR AI equivalent found
Amorepacific and LG H&H	losing to	APR's market cap (~KRW 8.5T) surpassed both by Aug 2025 (Amorepacific ~7T, LG H&H ~4.6T)

Questions people ask

Is APR Corporation profitable in 2025?: Yes. APR reported FY2025 consolidated revenue of KRW 1.53 trillion (about USD 1.05 billion), up 111% YoY, with operating profit of KRW 365.4 billion (+198% YoY) and a 24% operating margin, per company results dated 2026-02-04.
Who is Medicube's biggest competitor?: LG Household & Health Care's LG Pra.L device brand grew 447% in the five months after LG H&H acquired it in June 2025. Amorepacific is also contesting with AI-diagnostic tech like Skinsight (CES 2026 award) and its June 2026 Facial Aging Map.
Could AI replace Medicube's beauty devices?: Unlikely to replace the physical hardware, but rival Amorepacific has built AI-diagnostic layers (Skinsight, Dr. AMORE Facial Aging Map, June 2026) that APR has no public equivalent for as of July 2026, risking a differentiation gap rather than product replacement.
Is APR Corporation still growing in 2026?: Yes. Q1 2026 revenue reached KRW 593.4 billion, up 123.0% YoY, with operating profit of KRW 152.3 billion (+173.7% YoY) and overseas sales at roughly 90% of total, per results reported 2026-05-07.
Has APR overtaken Amorepacific and LG H&H in value?: By August 2025, APR's market cap reached about KRW 8.5 trillion, surpassing Amorepacific (~KRW 7 trillion) and LG H&H (~KRW 4.6 trillion). By May 2026 APR's cap had climbed to roughly KRW 16 trillion.
Is APR/Medicube facing any controversy in 2026?: In July 2026, APR publicly rebutted allegations that its '625% absorption rate' marketing claim echoed Korean War symbolism, releasing Tego Science lab test data in its defense; the controversy was still active as of July 7, 2026.

Timeline

2026-07-07APR rebuts Korean War marketing controversy over Medicube's 625% absorption claim
2026-06-20LG H&H reports LG Pra.L device sales up 447% in five months since June 2025 acquisition
2026-06-15Amorepacific unveils AI-powered Facial Aging Map using Dr. AMORE tech
2026-05-07APR Q1 2026 revenue hits KRW 593.4B, up 123% YoY, on Sephora and Nykaa expansion
2026-02-04APR reports FY2025 revenue KRW 1.53T with 24% operating margin
2026-01-26Medicube AGE-R device cumulative sales surpass 6 million units
2025-11-13Amorepacific's Skinsight AI diagnostic wins CES 2026 Innovation Award
2025-08-31APR market cap overtakes both Amorepacific and LG H&H
2025-06LG H&H acquires LG Electronics' beauty-device brand LG Pra.L
2024-02-27APR IPOs on KOSPI at KRW 250,000 per share

Head to head

APR Corporation vs LG Household & Health Care Ltd.

Revision history

26 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Nike E-Land World Ltd.Dr. Squatch